News | Proton Therapy | February 01, 2019

Stephenson Cancer Center is one of three locations in the world with Mevion’s S250i system with Hyperscan pencil beam scanning technology

University of Oklahoma Cancer Center Begins First Proton Therapy Treatments

February 1, 2019 — Home to the largest and most comprehensive radiation therapy program in Oklahoma, the Stephenson Cancer Center at OU (The University of Oklahoma) Medicine has commenced proton therapy treatments with the Mevion S250i Proton Therapy System with Hyperscan Pencil Beam Scanning. Cleared by the U.S. Food and Drug Administration (FDA) in 2017, Hyperscan improves on existing scanning capabilities to deliver conformal fields of therapeutic radiation to tumors faster with more precision.

“We are excited to offer our patients this advanced radiation therapy,” said Terence Herman, M.D., radiation oncologist at the Stephenson Cancer Center. “We provide a full range of treatment options, which ensures patients can stay in Oklahoma to receive the best possible care. Proton therapy is yet another important tool we can use in the fight against cancer, and the Mevion Hyperscan system provides a level of precision that far exceeds that of earlier, non-focused proton treatment techniques.”

As part of OU Medicine’s National Cancer Institute-designated cancer center, the single-room compact proton system is embedded directly into the radiation oncology department. This efficient approach enables the cancer center to share existing resources and give patients access to OU Medicine’s robust collection of cancer-fighting therapies under one roof.

OU Medicine anticipates using the new system to treat brain tumors, select head-and-neck tumors, abdominal tumors such as pancreatic cancer, some rare neural tumors, localized prostate cancer and essentially all tumors in pediatric patients. Several research projects are planned as well.

For more information: www.mevion.com


Related Content

News

Aug. 5, 2024 — Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that adding ...

Time August 09, 2024
arrow
News | PET-CT

July 31, 2024 — In a head-to-head comparison with FDG PET/CT, FDG PET/MRI demonstrated comparable or superior diagnostic ...

Time July 31, 2024
arrow
Feature | Radiation Oncology | By Christine Book

News emerging from several leading organizations and vendors in the radiation therapy arena came in at a fast pace in ...

Time July 30, 2024
arrow
News | Radiation Oncology

July 11, 2024 — The American Society for Radiation Oncology (ASTRO) issued the following statement from Jeff M ...

Time July 11, 2024
arrow
News | Radiation Oncology

July 9, 2024 — Insights from the latest Mordor Intelligence report, “Radiotherapy Market Size & Share Analysis - Growth ...

Time July 09, 2024
arrow
News | Prostate Cancer

July 5, 2024 — Lantheus Holdings, Inc., a leading radiopharmaceutical-focused company committed to enabling clinicians ...

Time July 05, 2024
arrow
News | Radiology Business

July 3, 2024 — The American Society of Radiologic Technologists has launched the BeRAD Professionalism Award to ...

Time July 03, 2024
arrow
News | Prostate Cancer

July 2, 2024 — A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, “Deep learning ...

Time July 02, 2024
arrow
News | Radiation Oncology

June 3, 2024 — The American Society for Radiation Oncology (ASTRO) published an updated clinical guideline that details ...

Time June 03, 2024
arrow
News | Oncology Information Management Systems (OIMS)

May 30, 2024 — RaySearch Laboratories AB announced the release of the latest version of RayCare, the next generation ...

Time May 30, 2024
arrow
Subscribe Now